#United States #Jersey City #RADICAVA #Shionogi #Tanabe Pharma

Tanabe Pharma America Transfers RADICAVA® Business to Shionogi

In a significant move to enhance its focus on future growth and innovation, Tanabe Pharma America, Inc. (TPA) has announced the transfer of its globally recognized RADICAVA® business to Shionogi Co., Ltd. This decision comes after the approval from the boards of directors of both companies, with the transaction agreement executed on December 22, 2025, marking a new chapter in the management of a leading treatment for Amyotrophic Lateral Sclerosis (ALS).

Commitment to ALS Community

RADICAVA® has established itself as a vital therapy in the battle against ALS, a debilitating disease that impacts many lives. The transfer aims not only to ensure continued access to RADICAVA® for patients but also to align it under a company with a strong commitment to rare diseases and an unwavering focus on the ALS community. Yasutoshi Kawakami, President of Tanabe Pharma America, expressed pride in RADICAVA®'s impact and emphasized that transitioning the business to Shionogi is a strategic move to enhance the treatment's reach for patients and caregivers who depend on it.

Key Transaction Details

Under the terms of the agreement, operations will continue seamlessly until the transaction is finalized, with Tanabe Pharma America assuming responsibility for the RADICAVA® business across North America until its completion. Shionogi is anticipated to take over the business fully as a subsidiary. The transaction is pending customary regulatory approvals with an expected closing date in the second quarter of 2026, ensuring that the current supply chain and product availability remain unaffected throughout the transition.

Advancing Patient-Centric Innovation

This strategic decision allows Tanabe Pharma America to reinforce its financial position and direct resources towards developing promising therapeutic pipelines. The overarching mission of the organization is to cultivate hope for those confronting illnesses, and through this transfer, they will continue to pursue innovative solutions through research and strategic partnerships. The shift to Shionogi also signifies an alignment with companies that prioritize developments aimed at addressing significant unmet medical needs.

About RADICAVA® and Its Significance

Approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022, RADICAVA ORS® (edaravone) serves an essential role in ALS treatment, having granted Orphan Drug Exclusivity due to its substantial contributions to patient care through an oral suspension method that circumvents the complications of intravenous administration. Unlike its predecessor, the oral form makes accessibility easier for patients, proving that Tanabe Pharma is devoted to improving not only the quality but also the delivery of patient care.

Since its introduction, RADICAVA® has provided therapy for over 19,000 ALS patients, translating into over 2.5 million therapy days and prescriptions from more than 2,600 healthcare providers across the United States. The effectiveness of this treatment and its ongoing monitoring for adverse reactions have underscored Tanabe Pharma's commitment to patient safety and improvement.

With ongoing research endeavors and a clear focus on expanding treatment accessibility, the RADICAVA® story continues as Tanabe Pharma America transitions towards a brighter future in ALS care. By combining forces with Shionogi, both entities are set to elevate their missions to ultimately better serve the ALS community and provide innovative solutions.

Conclusion

As this pivotal business transfer unfolds, the commitment to patients and the innovation of therapeutic solutions remains steadfast. Tanabe Pharma America continues to celebrate its heritage while embracing future opportunities, reflecting in its dedication to being a frontline resource for those affected by ALS. The transition not only signifies a strategic alignment of resources but also represents an enduring promise to foster advancements in patient care. With a legacy in place, the journey to enhance the lives of many individuals facing ALS continues with enthusiasm and hope.